UNSPSC 51202401: Adalimumab

This classification denotes a monoclonal antibody and biological response modifier with the molecular formula C6428H9912N1694O1987S46, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) FYS6T7F842, more generally known as adalimumab. European Medicines Agency schedules adalimumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20016. The term ADALIMUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 14, No. 3, 2000, List 44).

UNSPSC 51202401 Adalimumab is a Commodity code nominally identifying a specific pharmaceutical product, but recent state and local solicitations tagged with this code show substantial mismatch with the code's stated scope. The opportunities posted under this code encompass general medical and pharmaceutical procurement rather than adalimumab specifically: Seminole County, Florida is seeking naloxone and drug deactivation systems; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription programs; the City of Tampa is procuring medical and first aid supplies for emergency response; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing contracts for generic pharmaceuticals and over-the-counter products. The issuing bodies span state health agencies, county public health departments, municipal fire and rescue divisions, and cooperative purchasing consortia serving multiple jurisdictions. This fragmentation across issuing-body types and procurement mechanisms reflects the breadth of pharmaceutical and medical supply sourcing across state and local government.

The geographic spread includes Florida, Texas, Minnesota, and Oregon (through MMCAP participation), with no single state dominating recent activity. The most concrete recent opportunities are Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems, due July 26, 2026; the City of Tampa's IFB 26P00145 for medical and first aid supplies with an estimated contract value of $700,000.00, restricted to certified Small Local Business Enterprises (SLBEs) with a 5% bid discount, due March 13, 2026; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, open to manufacturers willing to work through designated wholesalers. The Texas HHS RFI HHS0017013, posted April 3, 2026, is exploratory rather than a binding solicitation and seeks vendor capability data on direct-to-manufacturer prescription models. The code shows limited alignment with its nominal scope—adalimumab itself does not appear in any of the recent opportunities, signaling either data-classification inconsistency or very narrow actual procurement activity under this specific commodity designation.